Kudesia, G, et al.
Changes in age related seroprevalence of antibody to varicella zoster virus: impact on vaccine strategy. Journal of Clinical Pathology
2002; 55: 154–155.
Manikkavasagan, G, et al.
The epidemiology of chickenpox in UK 5-year olds: an analysis to inform vaccine policy. Vaccine
2010; 28: 7699–7705.
Harger, JH, et al.
Risk factors and outcome of varicella-zoster virus pneumonia in pregnant women. Journal of Infectious Diseases
2002; 185: 422–427.
Tunbridge, AJ, et al.
Chickenpox in adults – clinical management. Journal of Infection
2008; 57: 95–102.
Daley, AJ, Thorpe, S, Garland, SM. Varicella and the pregnant woman: prevention and management. Australian and New Zealand Journal of Obstetrics and Gynaecology
2008; 48: 26–33.
Breuer, J. Vaccination to prevent varicella and shingles. Journal of Clinical Pathology
2001; 54: 743–747.
Bonanni, P, et al.
Varicella vaccination in Europe – taking the practical approach. BMC Medicine
2009; 7: 26.
Breuer, J. Live attenuated vaccine for the prevention of varicella-zoster virus infection: does it work, is it safe and do we really need it in the UK?
Journal of Medical Microbiology
2003; 52: 1–3.
Almuneef, M, et al.
Varicella zoster immunity in multinational health care workers of a Saudi Arabian hospital. American Journal of Infection Control
2003; 31: 375–381.
Baracco, GJ, et al.
Clinical and economic impact of various strategies for varicella immunity screening and vaccination of health care personnel. American Journal of Infection Control
2015; 43: 1053–1060.
Williams, V, Gershon, A, Brunell, PA. Serologic response to varicella-zoster membrane antigens measured by indirect fluorescence. Journal of Infectious Diseases
1974; 130: 669–672.
Gershon, AA, Krugman, S. Seroepidemiologic survey of varicella: value of specific fluorescent antibody test. Pediatrics
1975; 56: 1005–1008.
Grose, C, Edmond, BJ, Brunell, PA. Complement enhanced neutralizing antibody response to varicella-zoster virus. Journal of Infectious Diseases
1979; 139: 432–437.
Zaia, JA, Oxman, MN. Antibody to varicella-zoster virus-induced membrane antigen: immunofluorescence assay using monodisperse glutaraldehyde fixed target cells. Journal of Infectious Diseases
1977; 136: 519–530.
Grandien, M, et al.
Determination of varicella immunity by the indirect immunofluorescence test in urgent clinical situations. Scandinavian Journal of Infectious Diseases
1976; 8: 65–69.
Arvin, AM. Varicella vaccine – the first six years. New England Journal of Medicine
2001; 344: 1007–1009.
Ndumbe, PM, Cradock-Watson, J, Levinsky, RJ. Natural and artificial immunity to Varicella Zoster virus. Journal of Medical Virology
1988; 25: 171–178.
Wasmuth, EH, Miller, WJ. Sensitive enzyme-linked immunosorbent assay for antibody to Varicella-Zoster virus using purified VZV glycoprotein antigen. Journal of Medical Virology
1990; 32: 189–193.
Hammond, O, et al.
The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection. Journal of Medical Virology
2006; 78: 1679–1687.
Breuer, J, Schmid, DS, Gershon, AA. Use and limitations of varicella-zoster virus-specific serological testing to evaluate breakthrough disease in vaccinees and to screen for susceptibility to varicella. Journal of Infectious Diseases
2008; 197 (Suppl. 2): S147–151.
Michalik, DE, et al.
Primary vaccine failure after 1 dose of varicella vaccine in healthy children. Journal of Infectious Diseases
2008; 197: 944–949.
Sauerbrei, A, Wutzler, P. Serological detection of varicella-zoster virus-specific immunoglobulin G by an enzyme-linked immunosorbent assay using glycoprotein antigen. Journal of Clinical Microbiology
2006; 44: 3094–3097.
Chris Maple, PA, et al.
Performance characteristics of a quantitative, standardised varicella zoster IgG time resolved fluorescence immunoassay (VZV TRFIA) for measuring antibody following natural infection. Journal of Virological Methods
2009; 157: 90–92.
McDonald, SLR, et al.
Evaluation of the time resolved fluorescence immunoassay (TRFIA) for the detection of varicella zoster virus (VZV) antibodies following vaccination of healthcare workers. Journal of Virological Methods
2011; 172: 60–65.
Boxall, EH, et al.
Follow-up of pregnant women exposed to chicken-pox: an audit of relationship between level of antibody and development of chickenpox. European Journal of Clinical Microbiology and Infectious Diseases
2011; 30: 1193–1200.
Maple, PAC, et al.
Comparison of a commercial varicella zoster glycoprotein IgG enzyme immunoassay with a reference time resolved fluorescence immunoassay (VZV TRFIA) for measuring VZV IgG in sera from pregnant women, sera sent for confirmatory testing and pre and post-vOka vaccination sera from healthcare workers. Journal of Clinical Virology
2012; 53: 201–207.
Sauerbrei, A, et al.
Evaluation of three commercial varicella-zoster virus IgG enzyme-linked immunosorbent assays in comparison to the fluorescent-antibody-to-membrane-antigen test. Clinical and Vaccine Immunology
2012; 19: 1261–1268.
Lafer, MM, et al.
Comparative study of the standard fluorescent antibody to membrane antigen (FAMA) assay and a flow cytometry-adapted FAMA assay to assess immunity to Varicella-Zoster virus. Clinical and Vaccine Immunology
2011; 18: 1194–1197.
Vandersmissen, G, et al.
Occupational risk of infection by varicella zoster virus in Belgian healthcare workers: a seroprevalence study. Occupational and Environmental Medicine
2000; 57: 621–626.
Holmes, CN. Predictive value of a history of varicella infection. Canadian Family Physician
2005; 51: 60–65.
Hambleton, S, Gershon, AA. Preventing varicella-zoster disease. Clinical Microbiology Reviews
2005; 18: 70–80.
Maple, PAC, et al.
Performance of a time-resolved fluorescence immunoassay for measuring Varicella-Zoster virus immunoglobulin G levels in adults and comparison with commercial enzyme immunoassays and Merck glycoprotein enzyme immunoassay. Clinical and Vaccine Immunology
2006; 13: 214–218.
Nader, S, et al.
Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. Journal of Infectious Diseases
1995; 171: 13–17.
Gershon, AA, et al.
Immunization of healthy adults with live attenuated varicella vaccine. Journal of Infectious Diseases
1988; 158: 132–137.
Saiman, L, et al.
Persistence of immunity to varicella-zoster virus after vaccination of healthcare workers. Infection Control and Hospital Epidemiology
2001; 22: 279–283.
Kim, YH, et al.
Evaluation of a commercial glycoprotein enzyme-linked immunosorbent assay for measuring vaccine immunity to varicella. Yonsei Medical Journal
2014; 55: 459–466.